Table 1.
Genotypes of the MASP2 p.D120G mutation (A > G) in the groups of individuals analyzed
| N | A/A | A/G | G/G | Expected G/G1 | |
|---|---|---|---|---|---|
| Healthy adults | 1119 | 1063 (95.00) | 53 (4.74) | 3 (0.27) | 0.78 (0.07) |
| Adult no infection controls2 | 520 | 484 (93.08) | 36 (6.92) | 0 (0) | 0.62 (0.12) |
| Children no infection controls3 | 311 | 296 (95.18) | 14 (4.50) | 1 (0.32) | 0.21 (0.07) |
| Adult CAP patients | 1495 | 1414 (94.58) | 81 (5.42) | 0 (0) | 1.10 (0.07) |
| Children with IPD | 103 | 100 (97.09) | 3 (2.91) | 0 (0) | 0.02 (0.02) |
| SLE patients | 186 | 174 (93.55) | 12 (6.45) | 0 (0) | 0.19 (0.1) |
Values are number of individuals (%). CAP community-acquired pneumonia (including 73 patients with pleural empyema, 470 with severe sepsis, and 79 with acute respiratory distress syndrome), IPD invasive pneumococcal disease, SLE systemic lupus erythematosus
1Number of expected individuals homozygous for the G allele (%)
2Control group of 520 patients without history of relevant infectious diseases from the same origin as CAP patients
3Control group of children attended for minor surgery with no history of relevant respiratory diseases and without occurrence of inflammatory processes in at least 3 months previous to their inclusion